Vincent K Lam
Overview
Explore the profile of Vincent K Lam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
3.
4.
Kelly R, Anagnostou V, Lam V, Zaidi A
Clin Transl Med
. 2025 Feb;
15(2):e70223.
PMID: 39902711
No abstract available.
5.
Stalker M, Grady C, Watts A, Hwang W, Chandrasekhara K, Sun F, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100765.
PMID: 39758601
Introduction: Osimertinib is now a standard first-line (1L) therapy for EGFR-mutated (EGFRm) advanced NSCLC. We aimed to characterize patterns of therapy and longitudinal risk of brain and liver metastasis in...
6.
Grady C, Hwang W, Reuss J, Iams W, Cass A, Liu G, et al.
Pharmacoepidemiol Drug Saf
. 2024 Nov;
33(12):e70049.
PMID: 39586662
Introduction: Determining lines of therapy (LOT) using real-world data is crucial to inform clinical decisions and support clinical research. Existing rules for determining LOT in patients with metastatic non-small cell...
7.
Shaikh F, Lee S, White J, Zhao Y, Ferri J, Pereira G, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518082
: Preclinical and clinical data indicate that chemoradiotherapy (CRT) in combination with checkpoint inhibitors may prime an anti-tumor immunological response in esophageal cancer. However, responses to neoadjuvant therapy can vary...
8.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
9.
Tompkins W, Grady C, Hwang W, Chandrasekhara K, McCoach C, Sun F, et al.
JTO Clin Res Rep
. 2024 Aug;
5(8):100669.
PMID: 39157674
Introduction: Characteristics of long-term survivors in EGFR-mutant (EGFRm) NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era...
10.
Cheunkarndee T, Guo M, Houseknecht S, Feliciano J, Hann C, Lam V, et al.
JTO Clin Res Rep
. 2024 Jul;
5(6):100686.
PMID: 38975613
Introduction: Up to 20% of EGFR-mutated NSCLC cases harbor uncommon mutations, including atypical exon 19 and compound mutations. Relatively little is known about the efficacy of osimertinib in these cases....